IBD

Biotechnology company Galapagos will in-license drug targets for inflammatory bowel disease (IBD) which were discovered using a biology platform developed by Scipher Medicine. The move follows a deal Galapagos and Scipher Medicine made in 2020 to jointly validate a suite of novel IBD targets discovered by Scipher’s Spectra platform. Under the deal, Galapagos had the […]

Precision medicine technologies company Iterative Scopes has acquired two clinical trial optimisation companies focused on streamlining and accelerating the drug development process for inflammatory bowel disease (IBD).  The company has acquired Clinical Research Strategy Group, LLC and Precision Research (CRSG/Precision) in an effort to bolster its efforts in IBD clinical research. Iterative Scopes will use […]